CNS Pharmaceuticals, Inc. — Director's Dealing 2021

Nov 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CNS Pharmaceuticals, Inc. (CNSP)
CIK: 0001729427
Period of Report: 2021-11-19

Reporting Person: Downs Christopher (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-19	Common Stock	P	4500	$1.1537	Acquired	146500	Direct

Footnotes

F1: This transaction was executed in multiple trades at prices ranging from $1.14 to $1.155. The price reported above reflects the weighted average purchase
price. The reporting person hereby undertakes to provide upon upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of
shares and prices at which the transaction was effected.